Abstract
Objective To evaluate the clinical efficacy and safety of losartan potassium combined with alprostadil in the treatment of early diabetic nephropathy. Methods A total of 120 patients with early diabetic nephropathy were divided into three groups, 40 patients in every group.Patients in group A were given alprostadil 10 μg with 0.9% NaCl 50 mL daily 1 time.patients in group B were given losartan potassium daily 1 time 50 mg.And patients in group C were given alprostadil 10 μg with 0.9%NaC1 50 mL with losartan potassium 50 mg daily 1 time. After 3 months treatment, the clinical efficacy and serum blood urea nitrogen(BUN), serum creatinine(Scr)and urinary albumin excretion rate(UAER)were observed in three groups. Results ①Compared with before treatment, microalbuminuria and urinary albumin excretion rate in the three groups after treatment were much better improvement than before treatment(P 0.05). The BUN, Scr and UAER significantly decreased after treatment among three groups(P 0.05). Conclusions The clinical efficacy of losartan potassium combined with alprostadil is superior to the single drug in the treatment of early diabetic nephropathy which can decrease the BUN, Scr and UAER. Key words: Diabetic Nephropathies; Alprostadil
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
